Medical imaging advances and a growing interest in tissue perfusion for diagnostic and therapeutic applications are driving the perfusion imaging industry. Market trends show continual improvements to increase imaging quality, accuracy, and clinical value for perfusion imaging, which assesses blood flow in organs and tissues.
The perfusion imaging market is shaped by advances in MRI, CT, and PET. High-resolution imaging helps diagnose and monitor medical disorders by assessing tissue perfusion.
Quantitative perfusion analysis is growing. Clinicians may quantify blood flow characteristics using software and algorithms for more precise diagnosis and therapy planning.
AI is widely used in perfusion imaging to automate analysis and interpretation. AI methods improve picture processing, pattern recognition, and real-time perfusion parameter evaluation, speeding up and improving diagnostics.
DCE-MRI and DCE-CT are growing. These technologies follow contrast chemicals across tissues to reveal perfusion patterns and vascular anomalies.
Multimodal imaging for perfusion evaluation is a trend. Combining MRI and CT data increases tissue perfusion dynamics knowledge and diagnostic accuracy.
Neurology increasingly uses perfusion imaging for stroke and neurodegenerative diseases. Perfusion imaging detects and treats neurological disorders early by measuring cerebral blood flow.
Perfusion imaging is crucial for cancer detection and treatment. Dynamic contrast-enhanced imaging assesses tumor vascularity for characterisation, staging, and therapy response. Perfusion evaluations are critical to customized cancer treatment.
Myocardial blood flow assessment in cardiac perfusion imaging is improving. MPI and coronary CT angiography assess coronary artery disease, ischemia, and cardiac function.
Portable perfusion imaging devices are becoming more popular. Compact and handheld imaging instruments are versatile for point-of-care, emergency, and low-access imaging contexts.
Clinicians are increasingly using real-time perfusion monitoring to measure blood flow dynamics. In critical care, tissue perfusion data may guide therapies and improve patient outcomes.
Clinical research and medication development increasingly employ perfusion imaging. It is essential for evaluating new medicines, monitoring tissue perfusion changes, and developing new vascular abnormality medications.
Global perfusion imaging usage is rising across medical specialties. Perfusion imaging systems are in demand as developing nations expand healthcare infrastructure, offering market growth prospects.
In perfusion imaging, regulatory compliance and standardization are key developments. Perfusion imaging technologies are safe and reliable when regulated, boosting healthcare practitioners' trust and interoperability.
Perfusion Imaging Market Size was valued at USD 5.73 billion in 2023. The Perfusion Imagingmarket industry is projected to grow from USD 5.98 Billion in 2024 to USD 8.03 billion by 2032, exhibitinga compound annual growth rate (CAGR) of 3.75% during the forecast period (2024 - 2032). The rising occurrence of cardiovascular and respiratory diseases,along with the expanding elderly population and growing investments in cell-based research, are driving factors contributing to the market's growth. Several key market drivers are fueling the development of the perfusion imaging market.
September 2023: Philips unveiled a novel contrast-enhanced ultrasound application aimed at improving diagnostic certainty for individuals with cancer. The implementation of Philips Microvascular Imaging Super Resolution Contrast-Enhanced Ultrasound (CEUS) on the Philips Ultrasound System - EPIQ Elite - has resulted in a significant improvement in spatial resolution, with up to a 200% enhancement compared to earlier options. Philips' microvascular imaging enables medical personnel to observe the flow pattern of contrast material into a lesion and track its changes over time. This enhances their diagnostic certainty while evaluating uncertain lesions. Similar to other CEUS techniques, super resolution microvascular imaging (MVI) does not subject patients to ionizing radiation and is typically more cost-efficient and easily accessible. The adverse reaction rates to micro-bubble contrast media used for CEUS are significantly lower compared to iodinated contrast media. EPIQ Elite is a high-quality ultrasound device that integrates cutting-edge transducer technology and improved functionality to enhance clinical certainty and provide individualized care for patients. EPIQ Elite provides a diverse array of diagnostic apps and tools designed to cater to the requirements of different medical specialties. It offers outstanding clinical performance and efficient workflow management to address the demands of modern medical practices.
March 2022: Swift Medical, a world-renowned company specializing in digital wound care technology, introduced the Swift Ray 1. This innovative hardware device can be wirelessly connected to a smartphone camera and is capable of capturing detailed clinical data. Its purpose is to enhance the assessment, treatment, and monitoring of skin and wound conditions. The Swift Ray 1 is compact enough to be held in the hand of a clinician or patient, allowing for convenient access to high-quality medical imaging in various settings, including hospitals and homes. Moreover, this sophisticated imaging technology allows for the acquisition of precise clinical information for each patient, irrespective of their skin complexion, so promoting fairness and equality in wound care for all individuals. The Swift Ray 1 device records and analyzes crucial physiological traits of wounds that can reveal reasons for worry and/or inadequate healing, such as indications of infection, bacterial colonization, tissue compromise, perfusion, inflammation, and blood oxygenation levels. The new device utilizes long-wave infrared, near infrared, ultraviolet, and enhanced RGB imaging technologies to reveal hidden characteristics beneath the skin. This enables the device to support advanced clinical workflows.
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Cardiovascular diseases have emerged as one of the leading causes of mortality worldwide, resulting in a significant number of deaths each year. According to the World Health Organization (WHO), approximately 9.4 million deaths are attributed to cardiovascular diseases annually. The prevalence of these diseases has been steadily increasing, with around 17.5 million CVD-related deaths reported in 2012, projected to exceed 23.6 million by 2030. This rise in prevalence can be attributed to factors such as the increasing incidence of hypertension, a major risk factor for cardiovascular diseases and strokes. In 2013, it was estimated that ly, around 1 billion individuals were affected by hypertension, representing a 40% prevalence rate. Notably, the prevalence of hypertension varied across regions, with Africa having the highest prevalence at 46% and the Americas reporting the lowest at 35%. Chronic obstructive pulmonary disease (COPD) has also contributed to mortality rates, accounting for approximately 5% of total deaths in 2015, equating to around 3 million deaths.
The prevalence of COPD is expected to rise in the coming years due to increased tobacco consumption and growing pollution levels. In treating cardiac and respiratory diseases, perfusion systems play a crucial role by bypassing the cardiopulmonary systems during surgical interventions. These systems enable effective treatment of patients affected by these conditions. Perfusion systems play a critical role in the surgical treatment of patients with cardiac and respiratory diseases by circumventing the cardiopulmonary systems. These systems, including heart-lung machines, are designed to deliver oxygen and remove carbon dioxide from the blood when the natural functioning of the heart and lungs is impaired. As the prevalence of cardiovascular and respiratory diseases continues to increase ly, the demand for perfusion systems is expected to grow in the foreseeable future. These systems provide a vital lifeline for patients needing oxygenation and contribute significantly to their successful treatment and recovery. This factor drives the market growth.
Additionally, the rise in organ transplantations is a vital factor escalating the market growth. In addition, the surge in the aging population, increase in the incidence of multiple organ failures, rise in government and NGO initiatives to encourage organ donation, the surge in investments in cell-based research, advance in biologic manufacturing, increase in demand for non-invasive therapies and treatment, rise in the incidence of organ failures, the surge in healthcare outcomes and increased healthcare expenditure in both developed and developing regions, rise in initiatives to promote donations, and surge in incidences of chronic diseases coupled with the demand for organ donation are the major factors that drive the growth of the perfusion radiology market. The rise in nerve disorders and cardiovascular diseases resulting from changed lifestyles and unhealthy eating habits boosts the development of the perfusion radiology market. The American Heart Association Statistics Committee and the Stroke Statistics Subcommittee reported that approximately 795,000 people suffer from heart attacks yearly. These stats were released in 2017. Hence, there is an urgent need for government-funded programs, healthcare centers, and other bodies to develop ways to create awareness about the technological advancements that help track progress and cure the disease.Thus, driving the Perfusion Imaging market revenue.
Based on type, the Perfusion Imaging market segmentation includes computed tomography (C.T. scan), magnetic resonance imaging (MRI), and nuclear medicine. The computed tomography (C.T. scan) segment dominated the market; C.T. perfusion imaging is widely used to diagnose and monitor various conditions, including stroke, cancer, and cardiovascular diseases. C.T. scanners are widely available in healthcare facilities and offer fast imaging with high spatial resolution, making them a preferred choice for perfusion imaging.
Figure1 Perfusion Imaging Market, by Modality, 2023 &2032 (USD billion)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Based on Application, the Perfusion Imaging market segmentation includes myocardial perfusion, ventilation-perfusion, and functional brain imaging. The myocardial perfusion imagingsegment dominated the market; myocardial perfusion imaging is primarily used to assess blood flow in the heart muscle and identify areas of reduced blood supply. It plays a crucial role in diagnosing and managing cardiovascular diseases, such as coronary artery disease and myocardial infarction. Myocardial perfusion imaging techniques provide detailed information about the blood flow and function of the heart.
By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The North American perfusion imaging market will dominate, owing to the expanding occurrence pace of cardiovascular infections, cerebrum tumors, and tumor-related angiogenesis, among others will boost the market growth in this Region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure2 PERFUSION IMAGING MARKET SHARE BY REGION 2022 (%)
Source Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Perfusion Imaging market accounts for the second-largest market share due to the developing pervasiveness of neurological issues. Further, the German Perfusion Imaging market held the largest market share, and the U.K. Perfusion Imaging market was the fastest-growing market in the European Region.
The Asia-Pacific Perfusion Imaging Market is expected to grow fastest from 2024 to 2032. This is because of the enormous geriatric populace and the quickly creating regional economies. Moreover, China’s Perfusion Imaging market held the largest market share, and the IndianPerfusion Imaging market was the highest-growing market in the Asia-Pacific region.
Perfusion Imaging Key Market Players& Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the Perfusion Imaging market grow even more. Market participants are also undertaking different strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. The Perfusion Imaging industry must offer cost-effective items to expand and survive in a more competitive and rising market climate.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Perfusion Imaging industry to benefit clients and increase the market sector. The Perfusion Imaging industry has offered some of the most significant medical advantages in recent years. Major players in the Perfusion Imaging market, including General Electric Company (U.S.), Advantis Medical Imaging (Netherland), Aetna (U.S.), lathes Medical Imaging, Inc. (U.S.), Koninklijke Philips NV (Netherlands), Canon Medical Systems Corporation (Japan), Medtronic (Ireland), Siemens (Germany), Bracco Diagnostic, Inc. (Italy), Neusoft Corporation (China), Shimadzu Corporation (Japan), Perimed (U.S.), and others, are attempting to increase market demand by investing in research and development operations.
Medtronic plc is a well-established medical device company based in the United States. While its operational and executive headquarters are in Minneapolis, Minnesota, its legal offices are in Ireland. This is a result of Medtronic's acquisition of Covidien, an Irish-based healthcare product manufacturer, in 2015. By combining their expertise and resources, Medtronic aims to address healthcare challenges more effectively through continuous product development and the integration of innovative technologies.
CytoSorbents Corporation is a publicly traded company in Monmouth Junction, New Jersey. CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer.Terumo partnered with CytoSorbents Corporation (U.S.), a CytoSorb extracorporeal blood purification adsorber manufacturer. Terumo, a medical device company, has entered into a partnership to bring the CytoSorb extracorporeal blood purification adsorber to the market for cardiac surgery applications. The partnership enables the commercialization of CytoSorb in several European countries, including France, Sweden, Denmark, Norway, Finland, and Iceland. Through this collaboration, Terumo aims to expand the availability of CytoSorb and provide cardiac surgeons with a valuable tool for blood purification during surgical procedures.
Key CompaniesIn The Perfusion Imaging Market Include
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)